Taking into account all these anti-tumoral effects of anti-PCSK9 approaches and the existence of a wide variety of therapeutic strategies of the PCSK9 blockade (monoclonal antibodies, small molecule and peptide inhibitors, antisense oligonucleotides, siRNA, etc.), we believe this enzyme is a very valuable and attractive target for the potential treatment of liver cancers. The gene discussed is PCSK9; the disease is liver cancer.